Vigabatrin News

← Back to News Overview

---

Vigabatrin currently has 0 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Vigabatrin with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

• Original indication: Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: Treatment in monotherapy of infantile spasms (West's syndrome). Treatment in combination with other...
• Evidence level: L5
• Predicted indications (20):
  • West syndrome (99.1%)
  • intellectual disability, X-linked, with or without seizures, arx-related (98.7%)
  • episodic kinesigenic dyskinesia (97.3%)
  • developmental and epileptic encephalopathy (97.2%)
  • 1q44 microdeletion syndrome (96.7%)
  • PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation (96.6%)
  • DK1-CDG (96.5%)
  • microtriplication 11q24.1 (96.3%)
  • CCDC115-CDG (96.3%)
  • neonatal period electroclinical syndrome (96.2%)
  • genetic lethal multiple congenital anomalies/dysmorphic syndrome (96.2%)
  • COG2-CDG (96.2%)
  • colobomatous microphthalmia - obesity - hypogenitalism - intellectual disability syndrome (96.1%)
  • X-linked dominant intellectual disability-epilepsy syndrome (96.0%)
  • male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome (96.0%)
  • Jawad syndrome (96.0%)
  • muscular hypertrophy-hepatomegaly-polyhydramnios syndrome (96.0%)
  • infancy electroclinical syndrome (96.0%)
  • neonatal epileptic encephalopathy (95.9%)
  • craniofaciofrontodigital syndrome (95.9%)

View full drug report →

Related News (0)

No related news yet. When news mentions this drug, it will be collected and shown here automatically.

Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.